Immunoembolization using sargramostim or granulocyte-macrophage colony-stimulating factor (GM-CSF) involves the induction of tumor-specific B and T cells to produce local inflammation and regression of metastatic lesions [133]. Here, CSF2 is linked to neoplasm.